Novartis, Armed With New IP, Again Sues Over $3B MS Drug
Immediately after Novartis was granted a new patent Tuesday, the pharma giant sued a large group of generic-drug makers hoping to block their competing versions of its $3 billion multiple sclerosis...To view the full article, register now.
Already a subscriber? Click here to view full article